Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific CRM audit

This article was originally published in The Gray Sheet

Executive Summary

Firm anticipates FDA inspections of cardiac rhythm management facilities impacted by a December 2005 warning letter to Guidant to begin in the "coming weeks," CEO Jim Tobin said Oct. 18 during the firm's third-quarter earnings call (1"The Gray Sheet" Jan. 2, 2006, p. 3). The company is "ready," he says...

You may also be interested in...



Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested

Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel